SC-514

Catalog No.S4907 Batch:S490701

Print

Technical Data

Formula

C9H8N2OS2
Molecular Weight 224.3 CAS No. 354812-17-2
Solubility (25°C)* In vitro DMSO 45 mg/mL (200.62 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
2%DMSO 30%PEG300 2%Tween80 66%ddH2O
4.0mg/ml Taking the 1 mL working solution as an example, add 20 μL of 200 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 20 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 660 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SC-514 (GK 01140) is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
Targets
IKK2 [1] CDK2/CyclinA [1] AUR2 [1] PRAK [1] MSK [1]
3 μM-12 μM 61 μM 71 μM 75 μM 123 μM
In vitro SC-514 inhibits the native IKK complex or recombinant human IKK-1/IKK-2 heterodimer and IKK-2 homodimer similarly. SC-514 inhibits transcription of NF-κB-dependent IL-6, IL-8, and COX-2 genes in IL-1β-induced rheumatoid arthritis-derived synovial fibroblasts (RASFs) with IC50s of 20, 20 and 8 μM. 100 μM SC-514 blocks the phosphorylation and degradation of IκBα and also reduces the level of translocation of p65 into the nucleus in IL-1β-treated RASFs SC-514 does not inhibit the phosphorylation and activation of the IKK complex. SC-514 induces a delay but not a complete blockade in IκBα phosphorylation and degradation. SC-514 treatment cells shows a slightly slowed, decreased import of p65 into the nucleus and a faster export of p65 from the nucleus. SC-514 inhibits the phosphorylation of either IκBα or p65 similarly. [1]
In vivo SC-514 is efficacious in an acute model of inflammation, namely LPS-induced serum TNF-α production. SC-514 (50 mg/kg, i.p.) inhibits TNF-αproduction in vivo by ~70%. [1]

Protocol (from reference)

Selleck's SC-514 has been cited by 15 publications

Targetable leukemia dependency on noncanonical PI3Kγ signaling [ bioRxiv, 2023, 10.1101/2023.12.15.571909] PubMed: none
Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection [ Int J Mol Sci, 2022, 23(23)15000] PubMed: 36499329
USP12 promotes CD4+ T cell responses through deubiquitinating and stabilizing BCL10 [ Cell Death Differ, 2021, 10.1038/s41418-021-00787-y] PubMed: 33941870
Interferon-Inducible LINC02605 Promotes Antiviral Innate Responses by Strengthening IRF3 Nuclear Translocation [ Front Immunol, 2021, 12:755512] PubMed: 34804040
The HMGB1-AGER-STING1 pathway mediates the sterile inflammatory response to alkaliptosis [ Biochem Biophys Res Commun, 2021, 560:165-171] PubMed: 33992959
The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis. [ Hepatology, 2020, 10.1002/hep.31249] PubMed: 32221968
mTORC2 negatively controls the maturation process of medullary thymic epithelial cells by inhibiting the LTβR/RANK-NF-κB axis [ J Cell Physiol, 2020, 10.1002/jcp.30192] PubMed: 33269476
Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium. [ J Immunol, 2020, 20 pii: ji1901089] PubMed: 32312847
The effects of IKK-beta inhibition on early NF-kappa-B activation and transcription of downstream genes [Bloom MJ Cell Signal, 2019, 55:17-25] PubMed: 30543861
Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant Momordica charantia Induces Inflammatory Responses by Activating the NF-kappaB and JNK Pathways [ Toxins (Basel), 2019, 11(12)E694] PubMed: 31779275

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.